Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
The Pharmaceutical Market: Egypt
Management Report
Published: January 2010
Pages: 22
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 595.00 Buy Now!
Research from: Espicom
Sector: Prescription Medicines
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
According to the Economist Intelligence Unit (EIU), GDP is expected to reach US$391.0 billion in 2015, compared to US$211.9 billion in 2010. This positive economic performance is expected to result in increasing drug consumption. In demographic terms, Egypt has an estimated population of 84.8 million in 2010, which creates a constant demand for pharmaceuticals. However, Egypt’s demographic indicators reveal extremely high birth and infant mortality rates, which could impact negatively on the health system.
Healthcare provision is highly fragmented. While multiple providers offer greater patient choice, they can also add an element of confusion and lead to fragmentation of the healthcare system. The healthcare system has been in a transitory period for some time. While this should eventually result in a more modernised, efficient system, the delay has allegedly caused standards to slip in the public sector, with quality of provision varying between facilities.
Egypt is one of the leading pharmaceutical markets in Africa and the Middle East. The private pharmacy sector has increased by a high double digit CAGR in recent years, but per capita consumption is still low. Espicom expects that the market will continue to grow by a high CAGR in the 2010-2015 period. Considering opportunities beyond BRIC pharmaceutical markets, Egypt is becoming a very attractive market for multinational pharmaceutical companies focused on emerging markets.
The pharmaceutical industry has enjoyed a period of considerable development in recent years. There is a strong domestic production sector and while the majority is destined for the domestic market and imports play an important role, Egypt has emerged as a leading exporter of pharmaceuticals to Arab, Asian and Eastern European markets. Regulatory advancements in the internal market will increase manufacturing opportunities, although concerns remain regarding drug price referencing, introduced in 2009.
Public production represents around one tenth of the private pharmacy sector by value and nearly two tenths by volume. Public production is represented by the state-owned holding company HoldiPharma, which also owns a couple of pharmaceutical distributors. Due to increasing regulation affecting the distribution sector and the storage of biologics, HoldiPharma inaugurated its first cold chain pharmacy in 2009; biologic production is very expensive so most biologics are imported by one of Holdipharma’s distributors.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data, and healthcare personnel.
Healthcare provision is highly fragmented. While multiple providers offer greater patient choice, they can also add an element of confusion and lead to fragmentation of the healthcare system. The healthcare system has been in a transitory period for some time. While this should eventually result in a more modernised, efficient system, the delay has allegedly caused standards to slip in the public sector, with quality of provision varying between facilities.
Egypt is one of the leading pharmaceutical markets in Africa and the Middle East. The private pharmacy sector has increased by a high double digit CAGR in recent years, but per capita consumption is still low. Espicom expects that the market will continue to grow by a high CAGR in the 2010-2015 period. Considering opportunities beyond BRIC pharmaceutical markets, Egypt is becoming a very attractive market for multinational pharmaceutical companies focused on emerging markets.
The pharmaceutical industry has enjoyed a period of considerable development in recent years. There is a strong domestic production sector and while the majority is destined for the domestic market and imports play an important role, Egypt has emerged as a leading exporter of pharmaceuticals to Arab, Asian and Eastern European markets. Regulatory advancements in the internal market will increase manufacturing opportunities, although concerns remain regarding drug price referencing, introduced in 2009.
Public production represents around one tenth of the private pharmacy sector by value and nearly two tenths by volume. Public production is represented by the state-owned holding company HoldiPharma, which also owns a couple of pharmaceutical distributors. Due to increasing regulation affecting the distribution sector and the storage of biologics, HoldiPharma inaugurated its first cold chain pharmacy in 2009; biologic production is very expensive so most biologics are imported by one of Holdipharma’s distributors.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data, and healthcare personnel.